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zAppendix 1.
Alterations of the N-methyl-D-aspartate receptor (NMDAR) subunit GluN2A, encoded by GRIN2A, have been associated with a
spectrum of neurodevelopmental disorders with prominent speech-related features, and epilepsy. We performed a comprehensive
assessment of phenotypes with a standardized questionnaire in 92 previously unreported individuals with GRIN2A-related dis-
orders. Applying the criteria of the American College of Medical Genetics and Genomics to all published variants yielded 156
additional cases with pathogenic or likely pathogenic variants in GRIN2A, resulting in a total of 248 individuals. The phenotypic
spectrum ranged from normal or near-normal development with mild epilepsy and speech delay/apraxia to severe developmental
and epileptic encephalopathy, often within the epilepsy-aphasia spectrum. We found that pathogenic missense variants in trans-
membrane and linker domains (misTMD+Linker) were associated with severe developmental phenotypes, whereas missense variants
within amino terminal or ligand-binding domains (misATD+LBD) and null variants led to less severe developmental phenotypes,
which we confirmed in a discovery (P = 106) as well as validation cohort (P = 0.0003). Other phenotypes such as MRI abnorm-
alities and epilepsy types were also significantly different between the two groups. Notably, this was paralleled by electrophysiology
data, where misTMD+Linker predominantly led to NMDAR gain-of-function, while misATD+LBD exclusively caused NMDAR loss-of-
function. With respect to null variants, we show that Grin2a+ / cortical rat neurons also had reduced NMDAR function and there
was no evidence of previously postulated compensatory overexpression of GluN2B. We demonstrate that null variants and
misATD+LBD of GRIN2A do not only share the same clinical spectrum (i.e. milder phenotypes), but also result in similar electro-
physiological consequences (loss-of-function) opposing those of misTMD+Linker (severe phenotypes; predominantly gain-of-function).
This new pathomechanistic model may ultimately help in predicting phenotype severity as well as eligibility for potential precision
medicine approaches in GRIN2A-related disorders.
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Introduction
N-methyl-D-aspartate receptors (NMDAR) are expressed
throughout the brain, mediating excitatory neurotransmis-
sion important for development, learning, memory, and
other higher cognitive functions. NMDAR are di- or tri-
heterotetrameric ligand-gated ion channels composed of
two glycine-binding GluN1 (encoded by GRIN1) and two
glutamate-binding GluN2 subunits (GRIN2A–D)
(Traynelis et al., 2010). All GluN subunits are composed
of an extracellular, a transmembrane and an intracellular
component. The extracellular component consists of the
amino-terminal domain (ATD) with binding sites for antag-
onists such as Zn2+ and the ligand-binding domains (LBD)
S1 and S2 specific for agonist binding including glycine and
glutamate. The channel pore is formed by the three trans-
membrane domains (TMD), M1, M3, M4, and a re-entrant
pore-loop M2. The C-terminal domain (CTD) is involved
in mediating signals within the intracellular compartment.
Compared with the ubiquitously expressed GluN1 subunit,
the GluN2 subunits show specific spatiotemporal expres-
sion profiles throughout the CNS (Paoletti et al., 2013).
Whereas GluN2B and GluN2D subunits are predominantly
expressed prenatally, expression of GluN2A and GluN2C
is low prenatally but significantly increases shortly after
birth (Bar-Shira et al., 2015).
Four genes encoding NMDAR subunits (GRIN1,
GRIN2A, GRIN2B, and GRIN2D) have so far been
linked to human disease; GRIN2A appears to be associated
with the broadest and best characterized phenotypic spec-
trum, including a variety of disorders of the epilepsy apha-
sia spectrum and developmental and epileptic
encephalopathy, such as Landau-Kleffner syndrome and
epileptic encephalopathy with continuous spike-and-wave
during slow-wave sleep (CSWS) (Lemke et al., 2013
Lesca et al., 2013; Carvill et al., 2013).
GRIN2A is a gene with a significantly reduced number of
missense variants in controls compared to the expected
number of variants in a similarly sized gene (missense z-
score 3.8) (Lek et al., 2016). The ratio of 31.2 expected
versus 3 observed null variants in ExAC and the probabil-
ity of loss-of-function intolerance of 1.00 (pLI score) sug-
gests that GRIN2A null and missense variants strongly
reduce evolutionary fitness (Lek et al., 2016).
Investigation of functional consequences of disease-asso-
ciated GRIN2A missense variants revealed various gain- or
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loss-of-function effects (Endele et al., 2010; Lesca et al.,
2013; Pierson et al., 2014; Swanger et al., 2016; Addis
et al., 2017; Chen et al., 2017; Sibarov et al., 2017).
Identification of null variants likely leading to GluN2A
haploinsufficiency further complicated understanding of
underlying pathomechanisms. GluN2A haploinsufficiency
is expected to cause reduced expression of GluN2A,
which was thought to potentially be compensated for by
consecutive upregulation of expression of other GluN sub-
units, especially GluN2B, leading to an altered NMDAR
assembly (Balu and Coyle, 2011). NMDAR containing
GluN2B have slower deactivation times than those contain-
ing GluN2A (Paoletti et al., 2013; Wyllie et al., 2013).
Replacement of GluN2A by GluN2B has thus been
hypothesized to increase the duration of activation of the
NMDAR suggesting a net gain-of-function effect mediated
by GRIN2A null variants.
To delineate the phenotypic spectrum of GRIN2A-related
disorders, we reviewed previously reported and newly iden-
tified individuals with pathogenic or likely pathogenic vari-
ants in GRIN2A. We provide a comprehensive phenotypic
dataset of 248 individuals with variants in GRIN2A and
integrate these data with protein domain and electrophysio-
logical data. Specifically, we aimed at elucidating genetic
and functional correlates to the wide phenotypic range of
GRIN2A-related disorders, for which we reviewed pub-
lished electrophysiological data and investigated conse-
quences of Grin2a knock-out in cortical rat neurons.
Materials and methods
Cohort recruitment
Data on 92 previously unreported individuals with (likely)
pathogenic GRIN2A variants (ENST00000396573) were col-
lected from several diagnostic and research cohorts. Clinical
and genetic information were obtained with a specific ques-
tionnaire tailored to phenotypes previously reported in individ-
uals with GRIN2A variants (Supplementary Table 1). We also
ascertained additional, more detailed phenotypic information
on individuals that had previously been published. All infor-
mation about the listed variants has been added to an open-
access online database (www.grin-database.de).
Review of the literature and variant
classification
We searched the literature (www.ncbi.nlm.nih.gov/pubmed)
(up to 23 March 2018) for reports of cases with GRIN2A
variants and reviewed the associated clinical and genetic infor-
mation. This study has been approved by the ethics committee
of the University of Leipzig (224/16-ek, 402/16-ek).
Based on the recommendations of the American College of
Medical Genetics and Genomics (ACMG) (Richards et al.,
2015; Nykamp et al., 2017), we classified missense variants
fulfilling at least one of the following conditions (in addition
to constraint and prediction scores) as likely pathogenic:
de novo + absent from controls*
OR confirmative functional studies + absent from controls*
OR de novo + confirmative functional studies
OR present in three or more affected and no healthy indi-
viduals of one family + absent from controls*
OR novel missense variant at a location that had been clas-
sified as pathogenic according to the above conditions + absent
from controls*.
Furthermore, null variants located in exon 3–14 (until amino
acid position 838) were classified as (likely) pathogenic.
*Controls were over 120 000 people without severe paediat-
ric disease compiled in the gnomAD browser [genome
Aggregation Database (http://gnomad.broadinstitute.org/)].
Only variants classified as pathogenic or likely pathogenic
were considered for further genotype-phenotype correlations
in this study, regardless of the associated phenotype.
Statistical analysis
All statistical analyses were done with the R programming
language (www.r-project.org). Fisher’s exact test for Count
Data, Wilcoxon rank-sum test and Cochran Armitage
test were performed as referenced in the ‘Results’ section.
P-values were corrected for multiple testing with the
Bonferroni method. For Fisher’s exact test, we reported odds
ratios (OR) and 95% confidence intervals (95% CI). To inves-
tigate variant clustering in different phenotypes, we calculated
the distance (linear amino acid sequence) of all possible variant
pairs of individuals with the same intellectual disability/devel-
opmental delay (ID/DD) phenotypes to all combinations of
different ID/DD phenotypes (mild versus severe). We compared
the variant distances of same versus different phenotypes with
Wilcoxon rank-sum tests. The R code used to perform the
statistical analyses and figures is available upon request.
Ranking severity of intellectual
disability/developmental delay
We identified 178 individuals with detailed information about
the presence or absence of ID/DD and apportioned categories
reflecting the severity of the phenotype according to the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-5): no ID/DD (0 points), mild ID/DD (1 point), moder-
ate ID/DD (2 points), severe ID/DD (3 points), and profound
ID/DD (4 points) (Supplementary Table 4). The terms ID and
DD are used interchangeably here.
Neuronal culture, generation of the
Grin2a/ rat and RNA quantification
Cortical rat neurons were cultured as described (Baxter et al.,
2011) at a density of between 9–13  104 neurons per cm2
from embryonic Day 20.5 rats with NeurobasalTM growth
medium supplemented with B27 (Invitrogen). Experiments
were performed at days in vitro (DIV) 7–16, as indicated.
To generate the Grin2a/ rat, single cell Long Evans
Hooded rat embryos underwent pronuclear microinjection of
mRNA encoding the enzyme Cas9 and small guide RNAs
(sgRNA) binding to the 50 and 30 end of exon 8 of Grin2a,
before being implanted into pseudopregnant mothers. The re-
sulting live births were screened by polymerase chain reaction
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(PCR) for genomic deletions due to repair by non-homologous
end joining of double-stranded breaks targeted to either side of
exon 8. A 1065 bp deletion spanning exon 8 (which encodes
key pore forming domains of GluN2A) was identified, and
confirmed by sequencing (data not shown). Genotyping was
carried out using primer pairs P1 (AGGGAAGAAGG
GAACAGGAG) with P2 (TCTCTGGGATTCAGTGCAGA)
and P3 (AAGGCAGAGAGAGAGACAAAG) with P4 (ATGG
CAGTTCCCAGTAGCAT). P1 and P3 bind to the 50 end of
the deletion, P2 binds to the 30 end of the deletion, and P4
binds within the deletion. The sgRNA design and generation
of the founder animals was performed by Horizon Discovery
Group plc. All the experiments were performed using wild-
type, heterozygous, and homozygous littermate matched ani-
mals. Animals were treated and all experiments performed in
accordance with UK Animal Scientific Procedures Act (1986)
following local ethical review.
RNA was isolated from cultured neurons using the Roche
High Pure RNA Isolation Kit (including DNase treatment),
according to the manufacturer’s instructions (Roche). Three
wells from a 24-well plate were pooled for each animal.
cDNA was synthesized from 13 mg RNA using a
Transcriptor First Strand cDNA Synthesis Kit (Roche), accord-
ing to the manufacturer’s instructions, then stored at 20C.
For real time PCR (RT-PCR), cDNA was diluted to the
equivalent of 6 ng of initial RNA per 15 ml qPCR reaction,
per gene of interest. RT-PCR was performed in a Stratagene
Mx3000P QPCR System (Agilent Technologies), using the FS
universal SYBR Green MasterRox mix (Roche), according to
the manufacturer’s instructions. The required amount of tem-
plate was mixed with water, SYBR Green MasterRox mix and
forward and reverse primers (200 nM each final concentration)
to the required reaction volume. Primers used were: Grin2a:
AGCCAGAGACCCCGCTAC and TGGGGTGCACCTGGTA
AC; Gadph: AGAAGGCTGGGGCTCACC and AGTTGG
TGGTGCAGGATGC. Technical replicates as well as no tem-
plate and no reverse transcription negative controls were
included. The quantitative reverse transcriptase (qRT)-PCR
cycling programme was 10min at 95C, then 40 cycles of
30 s at 95C, 40 s at 60C, with detection of fluorescence
and 1min at 72C, followed by one cycle (for dissociation
curve) of 1min at 95C, and 30 s at 55C, with a ramp up
to 30 s at 95C, (ramp rate: 0.2C/s) with continuous detection
of fluorescence on the 55–95C ramp. Data were normalized
to Gadph expression.
Cell culture electrophysiological
recording and analysis
Coverslips containing cortical neurons were transferred to a
recording chamber perfused (at a flow rate of 3–5ml/min)
with an external recording solution composed of (in mM):
150 NaCl, 2.8 KCl, 10 HEPES, 2 CaCl2, 10 glucose and 0.1
glycine, pH 7.3 (320–330 mOsm). Tetrodotoxin (300 nM) was
included to block action-potential driven excitatory events.
Patch pipettes were made from thick-walled borosilicate glass
(Harvard Apparatus) and filled with a K-gluconate-based in-
ternal solution containing (in mM): potassium gluconate 141,
NaCl 2.5, HEPES 10, EGTA 11; pH 7.3 with KOH. Electrode
tips were fire-polished for a final resistance ranging between 3–
5 M. All NMDAR currents were evoked by 150 mM NMDA
and 100mM glycine, both applied using a perfusion system.
Currents were recorded at room temperature (21  2C) using
an Axopatch 200B amplifier (Molecular Devices). Neurons
were voltage-clamped at 65mV and recordings were rejected
if the holding current was 4100pA or if the series resistance
drifted by 420% of its initial value (520 M). Whole-cell
currents were analysed using WinEDR v3.2 software (John
Dempster, University of Strathclyde, UK). To determine the
ifenprodil sensitivity of neurons, whole-cell NMDAR currents
were recorded followed by the inclusion of 3mM ifenprodil in
the recording solution for a blocking period of 90 s. The
whole-cell NMDAR current was reassessed with 3 mM ifenpro-
dil included, and the % block was calculated. To determine
spermine potentiation, neurons were voltage-clamped at
30mV and switched to a low sodium recording solution
composed of (in mM): 70 NaCl, 60 choline chloride, 2.8
KCl, 20 HEPES, 10 glucose, 0.1 glycine, 0.1 diethylenetriami-
nepentaacetic acid, pH 6.5 with NaOH. NMDA currents were
evoked by 150 mM NMDA then reassessed in the presence of
100 mM spermine. Only cells with NMDA-evoked currents
440 pA were included.
Western blotting
Neurons were lysed in 1.5 lithium dodecyl sulphate sample
buffer (NuPage, Life Technologies) and boiled at 100C for
10min. Approximately 10 mg of protein was loaded onto a
precast gradient gel (4–12%) and subjected to electrophoresis.
Briefly, western blotting onto a polyvinylidene fluoride (PVDF)
membrane was then carried out using the Xcell SureLockTM
system (Invitrogen) according to the manufacturer’s instruc-
tions. Following the protein transfer, the PVDF membranes
were blocked for 1 h at room temperature with 5% (w/v)
non-fat dried milk in Tris-buffered saline with 0.1% Tween
20. The membranes were incubated at 4C overnight with the
primary antibodies diluted in blocking solution: anti-GluN2A
(N-terminus, 1:1000, Invitrogen), and anti-beta actin (1:200
000, Abcam) or anti-GluN2B C-terminus (1:8000, BD
Biosciences) and anti-beta actin. For visualization of western
blots, horseradish peroxidase-based secondary antibodies were
used followed by chemiluminescent detection on Kodak
X-Omat film.
Data availability
The authors confirm that the data supporting the findings of
this study are available within the article and/or its
Supplementary material.
Results
We reviewed data on 92 unpublished individuals with
(likely) pathogenic GRIN2A variants with systemically as-
sessed phenotypes. After re-evaluation of all published
GRIN2A variants based on ACMG recommendations
(Richards et al., 2015; Nykamp et al., 2017), we addition-
ally included 156 previously reported individuals with
(likely) pathogenic variants. Thus, we were able to collect-
ively review genotypes and phenotypes of 248 individuals
with GRIN2A-related disorders.
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The cohort
In our cohort, 45.1% of individuals whose gender was
known were female (n = 87) and 54.9% were male
(n = 106). Gender was unknown in 55 cases. The youngest
individual was 11 months at evaluation, the oldest 71 years
(median 8 years). Of the 248 individuals, 121 (121/248;
48.8%) were single cases, including 65 individuals (65/
121; 53.7%) where a de novo confirmation of the variant
was performed. The remaining 127 individuals (127/248;
51.2%) were found in 36 different families.
Among 3038 individuals with neurodevelopmental dis-
orders with epilepsy screened by epilepsy panel sequencing
(covering GRIN2A) in the same diagnostic lab, seven dis-
played (likely) pathogenic variants revealing a prevalence of
0.23% in this disease spectrum.
Variant type and distribution
One hundred and forty-five individuals (145/248; 58.5%)
had likely protein-truncating variants referred to as null
variants including 35 individuals (35/145; 24.1%) with
nonsense variants, 23 individuals (23/145; 15.9%) with
small frameshift deletions or duplications, 42 individuals
(42/145; 29.0%) with canonical splice-site variants, three
individuals (3/145; 2.1%) with a loss-of-start codon, 37
individuals (37/145; 25.5%) with gross deletions or dupli-
cations spanning up to the whole gene but not affecting
adjacent genes and five individuals (5/145; 3.4%) with
complex chromosomal rearrangements disrupting
GRIN2A (Fig. 1A). A total of 53 different null variants
were considered (likely) pathogenic, of which 22 were
recurrent.
The remaining 103 individuals (103/248; 41.5%) had
missense variants, including 13 individuals (13/103;
12.6%) with variants in the extracellular amino-terminal
domain and 56 individuals (56/103; 54.4%) with variants
in the extracellular ligand-binding domain S1 or S2, all of
which are referred to as misATD+LBD (for protein domains,
see Supplementary Table 5). In addition, six individuals
(6/103; 5.8%) had variants in linker regions and 28
individuals (28/103; 27.2%) had variants in the three trans-
membrane domains, M2–M4, referred to as misTMD+Linker.
No variants affecting the C-terminus met ACMG criteria of
being (likely) pathogenic (Fig. 1B). A total of 44 different
missense variants were considered (likely) pathogenic, of
which 23 were recurrent.
Intellectual disability/developmental
delay
In our GRIN2A cohort, cognitive assessment was available
on 177 individuals, of which 111 (111/177; 62.7%) had
ID/DD. In 35 cases (35/177; 19.8%), the severity of ID/DD
could not be specified in more detail. Among the 177 indi-
viduals, the level of ID/DD was mild in 35 cases (35/177;
19.8%), moderate in 17 (17/177; 9.6%), severe in eight
(8/177; 4.5%) and profound in 16 (16/177; 9.0%).
Sixty-six individuals (66/177; 37.3%) had normal intelli-
gence (Fig. 2A).
Seizures and electroencephalography
Information on the epilepsy phenotype was available in
219 cases. The majority of patients (192/219; 87.7%)
had seizures, including 121 individuals (121/219; 55.3%)
with focal seizures (with or without evolution to bilateral
tonic-clonic seizures). Twenty-one individuals (21/219;
9.6%) had tonic-clonic seizures of unknown onset, four
(4/219; 1.8%) epileptic spasms and 46 cases (46/219;
21.0%) had unspecified seizures. Several individuals
Figure 1 Distribution of variants. (A) Pathogenic or likely pathogenic null variants (red bars) are spread over nearly the entire gene.
However, according to ACMG criteria, the last exon 14 is spared, which encodes nearly the complete C-terminal domain. Null variants in healthy
gnomAD controls (black bars) occur primarily in the last exon 14 (probability loss-of-function intolerance 1.00 in ExAC). (B) Pathogenic or likely
pathogenic missense variants (red bars) cluster in regions of GRIN2A encoding functionally important domains (S1 and S2 ligand binding domains as
well as M1–M4 transmembrane domains and linker regions). The density of missense variants in healthy gnomAD controls (MAC = 2, black bars)
is highest in the intracellular C-terminal domain.
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displayed a spectrum of different seizure types. Twenty-
seven individuals (27/219; 12.3%) did not have seizures
(Fig. 2B).
EEG information was available in 152 individuals,
including 143 individuals (143/152; 94.1%) displaying epi-
leptiform discharges. In 86 cases (86/152; 56.6%), focal
discharges were recorded, of whom 34 cases (34/152;
22.4%) had centrotemporal spikes and 28 cases (28/152;
18.4%) had multifocal discharges. Fifty-one individuals
(51/152; 33.6%) had CSWS and six individuals (6/152;
3.9%) had generalized discharges. Only nine individuals
(9/152; 5.9%) had a normal EEG (Fig. 2C).
Recognizable epilepsy syndromes comprised the known
spectrum of GRIN2A-associated epilepsy syndromes, such
as benign epilepsy with centrotemporal spikes, atypical
childhood epilepsy with centrotemporal spikes and
Landau-Kleffner syndrome.
Language and speech disorders
Information about speech phenotypes was available in 140
cases. The vast majority of individuals presented with
speech disorders (129/140; 92.1%). In 115 patients where
the type of speech disorder was defined, 55 individuals (55/
140; 39.3%) had moderate speech/language impairment
including dysarthria, speech dyspraxia, dysphasia, speech
regression with residual impairments, sometimes supple-
mented by minor impairments such as impaired pitch,
hypernasality or imprecise articulation. Twenty-six individ-
uals (26/140; 18.6%) had aphasia (including speech regres-
sion with loss of speech) and 26 (26/140; 18.6%) had
isolated delay of speech development. Eight individuals
(8/140; 5.7%) presented with temporary speech regression.
The type of speech disorder was not further specified in 14
individuals (14/140; 10.0%). Only 11 individuals (11/140;
7.9%) had normal speech development. Speech disorders
were not necessarily linked to EEG abnormalities as 10/
11 individuals with normal speech development had abnor-
mal EEG and eight of nine individuals with normal EEG
still had abnormal speech development (only one individual
had normal speech, normal EEG, no epilepsy, no ID/DD)
(Fig. 2D).
Other neurological and psychiatric
phenotypes
Information about tone was available in 139 cases. Forty
(40/139; 28.8%) individuals had hypotonia, including 18
individuals (18/139; 13.0%) with no further specification.
Among the remaining 22 individuals, 16 (16/139; 11.5%)
had mild, two had moderate (2/139; 1.4%) and four indi-
viduals (4/139; 2.9%) had severe hypotonia (including one
individual with arthrogryposis). Ninety-nine individuals
(99/139; 71.2%) had no hypotonia (Supplementary Fig.
2A). We identified 19 (19/72; 26.4%) individuals with
movement disorders including ataxia (n = 10), dystonic/
spastic/choreatic movement disorders (n = 8), including
two individuals with complex movement disorders (n = 2;
Individual 039: no ambulation, spasticity, sometimes dys-
tonic, choreatic, athethotic movements; Individual 058: in-
voluntary movements, paroxysmal dyskinesia, movement
abnormality of the tongue, abnormality of eye movement,
impaired smooth pursuit), and an unspecified movement
Figure 2 Distribution of phenotypes. Individuals with GRIN2A-related disorders display a broad range of phenotype severity and expressivity
with respect to (A) intellectual outcome, (B) epilepsy, (C) EEG patterns, and (D) speech or language impairments.
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disorder (n = 1) (Supplementary Fig. 2B). Information
about neuropsychiatric comorbidities was available in 70
cases. Seventeen individuals (17/70; 24.3%) displayed be-
havioural or psychiatric disorders, such as attention deficit
hyperactivity disorder (n = 6), autism spectrum disorder
(n = 6), schizophrenia (n = 2) and anxiety disorder
(n = 1). Two individuals had unspecified behavioural
abnormalities.
MRI
Brain MRI data were available for 85 individuals.
Approximately 14% (12/85; 14.1%) had brain abnormal-
ities, comprising a variety of findings including focal cor-
tical dysplasia, dysplastic corpus callosum with delayed
myelinisation, hypoplasia of corpus callosum with midline
lipoma, hippocampal hyperintensity, hippocampal sclerosis,
heterotopia, subcortical lesion, hypoplastic olfactory bulb,
cerebellar glioma, enlarged Virchow-Robin spaces, delayed
myelinization (n = 1 for each). An additional 11% of
individuals (9/85; 10.6%) had generalized volume loss
compatible with brain atrophy. Abnormal gyral pattern
similar to some cases with GRIN1- and GRIN2B-related
disorders was not observed (Platzer et al., 2017; Fry et al.,
2018) and was also not expected in GRIN2A-related
disorders as knockdown of only GluN1 and GluN2B
(but not GluN2A) have been shown to slow down neur-
onal migration (Jiang et al., 2015). Sixty-four individuals
(64/85; 75.3%) had no MRI abnormalities (Supplementary
Fig. 2C).
Genotype–phenotype correlations
reveal two distinct phenotype groups
For 177 of all 248 individuals with (likely) pathogenic vari-
ants in GRIN2A, we obtained detailed information about
presence or absence of ID/DD and ranked severity of intel-
lectual disability into five categories (refer to the ‘Materials
and methods’ section).
Comparing 70 individuals with missense and 107
with null variants, we found more severe ID/DD in car-
riers of missense variants (Cochran Armitage Test,
P-value = 0.00011). However, individuals with missense
variants displayed a bimodal distribution of ID/DD severity
(Fig. 3A). We compared spatial variant clustering in indi-
viduals with same severity of ID/DD compared to variant
clustering in individuals with mixed severity of ID/DD
(Wilcoxon Rank test, comparing severe to mixed ID/DD
cases P-value = 2  106, comparing mild to mixed
ID/DD cases: P-value = 0.5) suggesting missense variants
in different parts of the protein lead to distinct ID/DD
phenotypes. We observed that 19 individuals with
misTMD+Linker had more severe phenotypes than 33 indi-
viduals with misATD+LBD (Fig. 3B). To test this observation
statistically, we randomly separated missense carriers into a
discovery cohort (n = 35) and a validation cohort (n = 17).
In the discovery cohort (Cochran Armitage Test, P = 106)
as well as the validation cohort (Cochran Armitage Test,
P = 0.0003), carriers of misTMD+Linker had significantly more
severe ranked ID/DD (mediandiscovery 4, medianvalidation 4) than
carriers of misATD+LBD (mediandiscovery 0, medianvalidation
0). Accordingly, 32 of 32 misTMD+Linker were de novo, while
18 of 47 misATD+LBD were de novo (Fisher’s exact test, OR
Inf, 95% CI 11 to Inf, P-value = 2  109). Other variants
were inherited; unknown variants were excluded from
the test.
Notably, carriers of the 107 null variants had a similar
degree of ID (median 1, mild ID) compared to carriers of
misATD+LBD (median 0 corresponding to no ID, Cochran
Armitage Test, P-value = 0.3). Furthermore, all 66 individ-
uals with normal intellect were carriers of misATD+LBD or
null variants.
We found significant differences for other phenotypes
only between individuals with misTMD+Linker and those
with misATD+LBD or null variants but not between those
with misATD+LBD and null variants (Fig. 4, all phenotype
comparisons in Fig. 4 were done with Fisher’s exact test).
Although we observed no difference for presence of epi-
lepsy in individuals with misTMD+Linker and individuals
with misATD+LBD or null variants (Fisher’s exact test, P-
value = 0.54), we found significant differences with respect
to seizure type as epileptic spasms were only observed in
individuals with misTMD+Linker, but not in individuals with
misATD+LBD or null variants (Fisher’s exact test, P-
value = 2.6  106). There were also significantly more
cases with focal seizures in the cohort with misATD+LBD/
null variants than in the misTMD+Linker cohort (Fisher’s
exact test, P-value = 4.1  104, OR 5.0, 95% CI 1.9 to
15.7). There were no significant differences for generalized
seizures (Fisher’s exact test, P-value = 1.0) or for particular
EEG patterns. All individuals with generalized volume loss
on MRI were carriers of misTMD+Linker (Fisher’s exact test,
P-value = 0.002, OR 5.8, 95% CI 1.7 to 21.3), while this
feature was not observed in any carrier of misATD+LBD/null
variants.
Variance of ID/DD phenotype in indi-
viduals with the same genetic variant
We investigated whether individuals with the same genetic
variant had similar ID/DD phenotypes (see ‘Materials and
methods’ section for classification). We investigated 98 in-
dividuals carrying 24 unique variants where ID/DD pheno-
types were available in at least two individuals per variant
(Fig. 5). The mean variance of ID/DD phenotypes per vari-
ant was 0.65 (0.64 standard deviation, SD). Permuting
family labels 10 000 times, we found that the real value
was lower than the mean variance in 15 of 10 000 permu-
tations (Supplementary Fig. 2, empirical P-value = 0.0016).
This suggests that while considerable phenotype expressiv-
ity exists, the same variant leads to similar ID/DD pheno-
types. However, more and better ID/DD data (e.g.
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Figure 4 Phenotypes correlated with protein domains. Comparison of phenotypes associated with variants in different protein domains
(Fisher’s exact test). Phenotype differences being significant after Bonferroni multiple testing correction for 17  2 tests are labelled red. For each
phenotype, OR with 95% CI (grey/red bars) and number of patients with the phenotype and number of patients for whom the phenotype was
assessed are shown. For clarity, OR and CIs are cut at 1.7. (A) Comparison misATD + LBD or null variants with misTMD + Linker.
CSWS = continuous spike-and-wave during slow-wave sleep; CTS = centrotemporal spikes.
Figure 3 Severity of ID/DD. Comparison of severity of ID/DD in carriers of variants in different protein domains. (A) Missense (blue) and null
(truncating) variants (yellow). (B) Missense variants in different protein domains in the order of the linear amino acid sequence and truncating
variants (far right). Here, variants that were inherited are coloured black, de novo variants are red and unknown variants are grey. Violins are
plotted to have the same maximum width. Bottom, middle and top of boxplots within violins show the 1st, 2nd and 3rd quartiles of the data;
whiskers maximally extend to 1.5 interquartile range.
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measured as IQ) is needed to optimally study phenotype
expressivity.
Both phenotype groups correspond
to opposing electrophysiological
consequences
Of the 44 (likely) pathogenic missense variants included in
this study (ATD: n = 4, LBD: n = 20, TMD: n = 16, Linker:
n = 4), 23 (equalling 52%) had been functionally investi-
gated previously (ATD: n = 3, LBD: n = 14, TMD2–4:
n = 1 each, Linker: n = 3). We compared the published
functional data of all 23 missense variants
(Supplementary Table 3) (Endele et al., 2010; Lesca et al.,
2013; Pierson et al., 2014; Serraz et al., 2016; Swanger
et al., 2016; Addis et al., 2017; Chen et al., 2017; Ogden
et al., 2017; Sibarov et al., 2017; XiangWei et al., 2018).
The 23 variants comprised six misTMD+Linker variants
displaying predominantly gain-of-function effects (5
gain-of-function versus 1 loss-of-function), while all 17
extracellular misATD+LBD variants show exclusively loss-
of-function activity (Fisher’s exact test, P-value = 2  104,
OR Inf, 95% CI 5.3 to Inf). We conclude that these oppos-
ing electrophysiological consequences are the most likely
explanation for the significantly different degree of severity
of ID/DD as well as other phenotypic differences associated
with misATD+LBD and misTMD+Linker. The currently single
exception to this pattern, the loss-of-function misTMD+Linker
variant c.1642G4A, p.(Ala548Thr), was found in an indi-
vidual with moderate ID. In total, 32 of 34 individuals with
misTMD+Linker had de novo variants, while two were of
unknown origin. On the other hand, the majority of the
variants in other regions were inherited.
Rat model and electrophysiological
analysis
Our phenotypic data suggest that the clinical consequences
of GRIN2A null variants are similar to the clinical conse-
quences of misATD+LBD loss-of-function variants. However,
it has previously been hypothesized that GRIN2A null vari-
ants could ultimately result in NMDAR with gain-of-func-
tion (or altered function) through compensatory increased
expression of other NMDAR subunits, particularly
Figure 5 Variance of ID/DD phenotype in individuals with the same genetic variant. ID/DD phenotypes (y-axis) of all recurrent
GRIN2A genetic variants are of similar degree suggesting that the same variant leads to similar ID/DD phenotypes despite considerable phenotype
expressivity.
88 | BRAIN 2019: 142; 80–92 V. Strehlow et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/1/80/5240919 by R
adboud U
niversity N
ijm
egen user on 18 M
ay 2020
GRIN2B. We therefore sought to determine whether
homozygous or heterozygous loss of Grin2a results in com-
pensatory upregulation of Grin2b expression. We used a
newly created Grin2a knockout rat, and compared
NMDAR currents in cortical neurons cultured from these
rats with those from their wild-type and heterozygous lit-
termates (litters generated by Het-Het crosses) (Fig. 6A). In
this model, there is no detectable compensatory increase in
the expression level of GluN2B protein (Fig. 6B). We ana-
lysed NMDAR currents at two developmental stages:
after 7–8 DIV when currents are almost exclusively
GluN2B-dominated, and at 15–16 DIV when there is a
significant proportion of GluN2A-containing NMDARs
(Supplementary Fig. 3) (Edman et al., 2012). Analysis of
NMDAR current density at 7–8 DIV revealed no genotype-
dependent difference, consistent with the near-exclusive
Figure 6 No compensation by GluN2B. GluN2B-mediated currents do not increase to compensate for GluN2A deficiency in cortical
neurons from a Grin2a knock-out rat. (A) Western blot and quantification confirming the absence of GluN2A expression in Grin2a/ neurons,
and an intermediate expression level in Grin2a+ / neurons at 15 DIV. Tukey’s test reveals a significant difference between Grin2a+ / + versus
Grin2a+ / (P = 0.0196) and versus Grin2a/ (P = 0.0014). Grin2a+ / + : n = 6; Grin2a+ /: n = 5; Grin2a/: n = 5. (B) Western blot and quantification
confirming no changes in GluN2B expression in either Grin2a+ / or Grin2/ neurons compared to Grin2a+ / + neurons at 15 DIV. Grin2a+ / + , n = 6;
Grin2a+ /: n = 5; Grin2a/: n = 5. (C) NMDA (150mM) evoked currents were measured in cortical neurons of the indicated genotypes and periods
of culture. Currents were calculated and normalized to cell capacitance to give a value for the current density within the neuron. Two-way ANOVA
reports a significant developmental stage effect (P5 0.0001) and a significant genotype effect (P = 0.013) as well as a significant interaction between
the two (P = 0.0059). Sidak’s post hoc test reveals a significant difference between Grin2a+ / + versus Grin2a+ / (P = 0.0007) and versus Grin2a/
(P = 0.0006). Grin2a+ / + : n = 38 (7–8 DIV), 38 (15–16 DIV) cells, eight animals; Grin2a+ /: n = 40 (7–8 DIV), 35 (15–16 DIV) cells, nine animals;
Grin2a/: n = 48 (7–8 DIV), 31 (15–16 DIV) cells, 10 animals. (D) NMDA (150mM) evoked currents were measured in cortical neurons of the
indicated genotypes and periods of culture before and after the application of the GluN2B-selective antagonist ifenprodil (3mM). The ifenprodil-
sensitive current was calculated and normalized to cell capacitance. Two-way ANOVA reports a significant developmental stage effect (P5 0.0001)
but no significant genotype effect (P = 0.880) nor a significant interaction between the two (P = 0.154). Grin2a+ / + : n = 13 (7–8 DIV), 13 (15–16 DIV)
cells, four animals; Grin2a+ /: n = 13 (7–8 DIV), 11 (15–16 DIV) cells, five animals; Grin2a/: n = 17 (7–8 DIV), 16 (15–16 DIV) cells, five animals. (E)
At 15–16 DIV the percentage inhibition of NMDA (150mM) evoked currents by ifenprodil (3mM) was significantly greater (Tukey’s test) in Grin2a/
neurons compared to Grin2a+ / + neurons (P5 0.0001) and Grin2a+ / neurons (P = 0.0038). DIV = day in vitro.
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presence of GluN2B-containing diheteromeric NMDARs
(Fig. 6C). Analysis of currents at 15–16 DIV showed an
age-dependent increase of currents, as expected, but also a
deficit in currents in Grin2a + / and Grin2a/ neurons,
relative to wild-type. This suggests that any compensation
of GluN2A deficiency through an increase in other
NMDAR subunits is insufficient to rescue currents to
wild-type levels.
We next investigated whether there was any evidence of
compensation through GluN2B upregulation that could be
detected via electrophysiological assessment. If there was
compensation, then the magnitude of whole cell currents
dependent on GluN2B would be expected to be higher in
Grin2a + / and Grin2a/ neurons, relative to wild-type, at
15–16 DIV. We measured the portion of the whole cell
currents sensitive to the GluN2B-selective antagonist ifen-
prodil (Fig. 6D), but found no difference in the magnitude
of ifenprodil-sensitive current at 15–16 DIV (or 7–8 DIV).
Nevertheless, the percentage of total NMDAR currents sen-
sitive to ifenprodil block was increased in Grin2a/ neu-
rons as would be expected for neurons where GluN2A
expression is absent (Fig. 6E). Thus, within this experimen-
tal system, there appears to be no evidence for increases in
GluN2B expression to compensate for loss of GluN2A ex-
pression due to Grin2a allelic deletion.
Discussion
We present a comprehensive investigation of GRIN2A-
related phenotypes, comprising 248 affected individuals
with pathogenic or likely pathogenic variants in GRIN2A.
Variant distribution
We observed a clustering of disease-causing missense vari-
ants in the highly conserved ligand-binding domains S1 and
S2 as well as transmembrane and linker domains, which is
similar to our previous observations in GRIN1 and
GRIN2B (Lemke et al., 2016; Platzer et al., 2017) and
may assist in predicting pathogenicity of variants of uncer-
tain significance by its location (Fig. 1). No missense vari-
ants in the intracellular C-terminal domain of GluN2A
(beyond amino acid position 838) have been found to
fulfil ACMG criteria for being pathogenic or likely patho-
genic. Previous reports of alleged disease-associated C-ter-
minal variants may therefore be revised, as this region is
also the only region in GRIN2A that shows no evidence of
regional depletion as the number of observed variants in
ExAC was not higher than expected by a mutational model
(Lek et al., 2016; Samocha, 2017), similar to GluN1 and
GluN2B (Lemke et al., 2016; Platzer et al., 2017). As the
C-terminus of GluN2A is tolerant to genetic variation in
the general population, we conclude that most missense
variants in the C-terminus likely have no effects.
Phenotypic range
Our comprehensive analysis shows that the GRIN2A-related
phenotypic spectrum does not only comprise well established
epilepsy-aphasia disorders, but is much broader and ranges
from normal or near-normal development to non-specific
developmental and epileptic encephalopathy. Notably, only
three individuals had an apparently normal phenotype with
no ID, no epilepsy and no speech disorder (two of them also
had EEG investigation, both with normal result), and all
were relatives of more severely affected individuals.
Moreover, five individuals with (likely) pathogenic variants
are listed in gnomAD and can therefore also be considered
normal, even though very minor phenotypic abnormalities
cannot be excluded. Thus, reduced penetrance appears to be
possible but not a common phenomenon among carriers of
pathogenic or likely pathogenic GRIN2A variants. Epilepsy
and speech disorders seen in 480% of individuals occur
independent of intellectual disability, which is present in
62.7% of individuals and was mild in nearly half of those
cases. This is in stark contrast to phenotypes related to
GRIN1, GRIN2B and GRIN2D that are associated with
marked ID in nearly 100% of cases (Lemke et al., 2016;
Li et al., 2016; Platzer et al., 2017). Among all currently
known GRIN-associated phenotypes, GRIN2A-related dis-
orders display the most recognizable epilepsy spectrum, com-
prising focal or multifocal epilepsy with or without
centrotemporal spikes as well as CSWS (Fig. 2). As normal
and near-normal development are part of the phenotypic
range, it can be assumed that individuals with milder pheno-
types are more likely to pass on their pathogenic variants,
which may explain why 60.2% of variants of known origin
are inherited and do not exclusively occur de novo, as is the
rule for disorders related to GRIN1, GRIN2B and
GRIN2D (Lemke et al., 2016; Li et al., 2016; Platzer
et al., 2017).
Genotype–phenotype correlation
In contrast to previous studies (Myers and Scheffer, 1993),
our systematic analyses of phenotype and molecular data of
a large cohort of individuals with GRIN2A variants iden-
tified two distinct phenotype groups corresponding to the
location of variants in different protein domains (Fig. 4).
MisTMD+Linker are associated with severe developmental
and epileptic encephalopathy phenotypes, whereas
misATD+LBD are associated with speech abnormalities and/
or seizures with mild to no ID only. Strikingly, both pheno-
typic groups are significantly correlated with opposing elec-
trophysiological consequences of the NMDAR, even
though the complex functional alterations caused by a
GRIN2A variant cannot always easily be reduced to a
binary description such as loss- or gain-of-function. It ap-
pears plausible that misLBD may impede agonist binding
and thus reduce channel activity, whereas a misTMD+Linker
may affect formation of the ion channel pore mediating a
gain-of-function effect by e.g. disrupted channel inhibition
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by Mg2+ (Pierson et al., 2014; Swanger et al., 2016; Addis
et al., 2017; Chen et al., 2017). However, more electro-
physiology data of mutated NMDAR are needed to clarify
exact pathomechanisms of variants in the different protein
domains.
Pathomechanistic model
We observed that individuals with extracellular
misATD+LBD (displaying exclusively loss-of-function effects)
have a comparable phenotypic range to individuals with
null variants, which is substantially less severe than the
phenotypes of individuals with membrane-associated
misTMD+Linker (displaying predominantly gain-of-function
effects). We therefore hypothesize that loss-of-function
misATD+LBD and null variants mediate similar pathomecha-
nistic effects.
In agreement with our phenotype data but in contrast to
previous hypotheses, we observed that Grin2a/ + and
Grin2a/ cultured rat neurons show lower current density,
indicating that any compensatory increase in expression of
other GluN subunits is not sufficient to match the current
normally mediated by GluN2A-containing NMDAR in
rats. Furthermore, application of the GluN2B-specific
blocker ifenprodil to these neurons did not give any evi-
dence of compensatory increase of GluN2B in NMDAR
assembly in GluN2A-deficient cells. Our data thus contra-
dict the hypothesis of a compensatory gain-of-function
effect due to GluN2A haploinsufficiency and in fact suggest
loss-of-function, in agreement with our phenotype-based
observations. Namely, GRIN2A null variants are asso-
ciated with comparable clinical consequences as
misATD+LBD (resulting in loss-of-function) and with mark-
edly less severe clinical consequences than misTMD+Linker
(resulting predominantly in gain-of-function). With our
pathomechanistic model, we predict that individuals with
developmental and epileptic encephalopathy due to
misTMD+Linker are prone to having an underlying gain of
NMDAR function and represent promising candidates for
treatment with NMDAR blockers, such as memantine
(Pierson et al., 2014). However, currently there are still
little data available on clinical treatment of GRIN2A-
related disorders with memantine (Pierson et al., 2014).
Conversely, individuals with variants leading to complete
or partial loss of channel function (misATD+LBD or null
variants) may potentially respond to positive allosteric
modulators of the NMDAR (Zhu and Paoletti, 2015;
Addis et al., 2017).
Our study illustrates how systematically investigating
clinical phenotypes in a large cohort of individuals with a
monogenic disease cannot only reveal novel genotype-
phenotype correlations, but also contribute to a better
understanding of the underlying functional mechanisms
being a prerequisite for the development of precision medi-
cine approaches.
Acknowledgements
We thank J. McQueen for providing the data illustrated in
Fig. 6B. We thank G. Derksen-Lubsen, T. Dijkhuizen, N.
Doornebal, F.E. Jansen, E.K. Vanhoutte for their support
and helpful discussion.
Funding
H.O.H. was supported by stipends of the German Federal
Ministry of Education and Research (BMBF), (FKZ:
01EO1501) and the German Research Foundation, (DFG
HE7987/1-1/1-2). KFMM was supported by a Wellcome
Trust Clinical PhD Fellowship (102838). G.M. was sup-
ported by the National Institute of Neurological
Disorders and Stroke, (NINDS K08NS092898) and
Jordan’s Guardian Angels. IH was supported by intramural
funds of the University of Kiel, the German Research
Foundation (DFG HE5415/3-1) within the
EuroEPINOMICS framework of the European Science
Foundation (DFG HE5415/5-1/6-1). Generation of the
Grin2a/ rat was supported by funds from the
Department of Biotechnology, Government of India.
Competing interests
The authors report no competing interests.
Supplementary material
Supplementary material is available at Brain online.
Appendix 1
GRIN2A study group
Full affiliation details are available in the Supplementary
material.
Alexis Arzimanoglou, Paul B. Augustijn, Patrick Van
Bogaert, Helene Bourry, Peter Burfeind, Yoyo Chu, Brian
Chung, Diane Doummar, Patrick Edery, Aviva Fattal-
Valevski, Me´lanie Fradin, Marion Gerard, Christa de
Geus, Boudewijn Gunning, Danielle Hasaerts, Ingo
Helbig, Katherine L. Helbig, Rami Jamra, Me´lanie
Jennesson Lyver, Jolien S. Klein Wassink-Ruiter, David A.
Koolen, Damien Lederer, Roelineke J. Lunsing, Mikae¨l
Mathot, He´le`ne Maurey, Shay Menascu, Anne Michel,
Ghayda Mirzaa, Diana Mitter, Hiltrud Muhle, Rikke S.
Møller, Caroline Nava, Margaret O’Brien, Evelyn van
Pinxteren-Nagler, Anne van Riesen, Christelle Rougeot,
Damien Sanlaville, Jolanda H. Schieving, Steffen Syrbe,
Hermine E. Veenstra-Knol, Nienke Verbeek, Dorothe´e
GRIN2A-related disorders BRAIN 2019: 142; 80–92 | 91
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/1/80/5240919 by R
adboud U
niversity N
ijm
egen user on 18 M
ay 2020
Ville, Yvonne J. Vos, Pascal Vrielynck, Sabrina Wagner,
Sarah Weckhuysen, Marjolein H. Willemsen.
References
Addis L, Virdee JK, Vidler LR, Collier DA, Pal DK, Ursu D. Epilepsy-
associated GRIN2A mutations reduce NMDA receptor trafficking
and agonist potency–molecular profiling and functional rescue. Sci
Rep 2017; 7: 66.
Balu DT, Coyle JT. Glutamate receptor composition of the post-syn-
aptic density is altered in genetic mouse models of NMDA receptor
hypo–and hyperfunction. Brain Res 2011; 1392: 1–7.
Bar-Shira O, Maor R, Chechik G. Gene expression switching of re-
ceptor subunits in human brain development. PLoS Comput Biol
2015; 11: e1004559.
Baxter PS, Martel MA, McMahon A, Kind PC, Hardingham GE.
Pituitary adenylate cyclase-activating peptide induces long-lasting
neuroprotection through the induction of activity-dependent signal-
ing via the cyclic AMP response element-binding protein-regulated
transcription co-activator 1. J Neurochem 2011; 118: 365–78.
Carvill GL, Regan BM, Yendle SC, O’Roak BJ, Lozovaya N, Bruneau
N, et al. GRIN2A mutations cause epilepsy-aphasia spectrum dis-
orders. Nat Genet 2013; 45: 1073–6.
Chen W, Tankovic A, Burger PB, Kusumoto H, Traynelis SF, Yuan H.
Functional evaluation of a de novo GRIN2A mutation identified in a
patient with profound global developmental delay and refractory
epilepsy. Mol Pharmacol 2017; 91: 317–30.
Edman S, McKay S, Macdonald LJ, Samadi M, Livesey MR,
Hardingham GE, et al. TCN 201 selectively blocks GluN2A-con-
taining NMDARs in a GluN1 co-agonist dependent but non-com-
petitive manner. Neuropharmacology 2012; 63: 441–9.
Endele S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I,
et al. Mutations in GRIN2A and GRIN2B encoding regulatory sub-
units of NMDA receptors cause variable neurodevelopmental
phenotypes. Nat Genet 2010; 42: 1021–6.
Fry AE, Fawcett KA, Zelnik N, Yuan H, Thompson BAN, Shemer-
Meiri L, et al. De novo mutations in GRIN1 cause extensive bilat-
eral polymicrogyria. Brain 2018; 141: 698–712.
Jiang H, Jiang W, Zou J, Wang B, Yu M, Pan Y, et al. The GluN2B
subunit of N-methy-D-asparate receptor regulates the radial migra-
tion of cortical neurons in vivo. Brain Res 2015; 1610: 20–32.
Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T,
et al. Analysis of protein-coding genetic variation in 60706 humans.
Nature 2016; 536: 285–91.
Lemke JR, Geider K, Helbig KL, Heyne HO, Schutz H, Hentschel J,
et al. Delineating the GRIN1 phenotypic spectrum: a distinct genetic
NMDA receptor encephalopathy. Neurology 2016; 86: 2171–8.
Lemke JR, Lal D, Reinthaler EM, Steiner I, Nothnagel M, Alber M,
et al. Mutations in GRIN2A cause idiopathic focal epilepsy with
rolandic spikes. Nat Genet 2013; 45: 1067–72.
Lesca G, Rudolf G, Bruneau N, Lozovaya N, Labalme A, Boutry-
Kryza N, et al. GRIN2A mutations in acquired epileptic aphasia
and related childhood focal epilepsies and encephalopathies with
speech and language dysfunction. Nat Genet 2013; 45: 1061–6.
Li D, Yuan H, Ortiz-Gonzalez XR, Marsh ED, Tian L, McCormick
EM, et al. GRIN2D Recurrent de novo dominant mutation causes a
severe epileptic encephalopathy treatable with NMDA receptor
channel blockers. Am J Hum Genet 2016; 99: 802–16.
Myers KA, Scheffer IE. GRIN2A-related speech disorders and epilepsy.
In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH,
Stephens K, et al., editors. GeneReviews((R)). Seattle, WA:
University of Washington; 1993.
Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY,
et al. Sherloc: a comprehensive refinement of the ACMG-AMP vari-
ant classification criteria. Genet Med 2017; 19: 1105–17.
Ogden KK, Chen W, Swanger SA, McDaniel MJ, Fan LZ, Hu C, et al.
Molecular mechanism of disease-associated mutations in the Pre-M1
helix of NMDA receptors and potential rescue pharmacology. PLoS
Genet 2017; 13: e1006536.
Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity:
impact on receptor properties, synaptic plasticity and disease. Nat
Rev Neurosci 2013; 14: 383–400.
Pierson TM, Yuan H, Marsh ED, Fuentes-Fajardo K, Adams DR,
Markello T, et al. GRIN2A mutation and early-onset epileptic en-
cephalopathy: personalized therapy with memantine. Ann Clin
Transl Neurol 2014; 1: 190–8.
Platzer K, Yuan H, Schutz H, Winschel A, Chen W, Hu C, et al. GRIN2B
encephalopathy: novel findings on phenotype, variant clustering, functional
consequences and treatment aspects. J Med Genet 2017; 54: 460–70.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al.
Standards and guidelines for the interpretation of sequence variants:
a joint consensus recommendation of the American college of med-
ical genetics and genomics and the association for molecular path-
ology. Genet Med 2015; 17: 405–24.
Samocha KE. Regional missense constraint improves variant deleter-
iousness prediction. bioRxiv 2017; doi: 10.1101/148353. https://
www.biorxiv.org/content/early/2017/06/12/148353.
Serraz B, Grand T, Paoletti P. Altered zinc sensitivity of NMDA re-
ceptors harboring clinically-relevant mutations. Neuropharmacology
2016; 109: 196–204.
Sibarov DA, Bruneau N, Antonov SM, Szepetowski P, Burnashev N,
Giniatullin R. Functional properties of human NMDA receptors
associated with epilepsy-related mutations of GluN2A subunit.
Front Cell Neurosci 2017; 11: 155.
Swanger SA, Chen W, Wells G, Burger PB, Tankovic A, Bhattacharya
S, et al. Mechanistic insight into NMDA receptor dysregulation by
rare variants in the GluN2A and GluN2B agonist binding domains.
Am J Hum Genet 2016; 99: 1261–80.
Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM,
Ogden KK, et al. Glutamate receptor ion channels: structure, regu-
lation, and function. Pharmacol Rev 2010; 62: 405–96.
Wyllie DJ, Livesey MR, Hardingham GE. Influence of GluN2 subunit
identity on NMDA receptor function. Neuropharmacology 2013;
74: 4–17.
XiangWei W, Jiang Y, Yuan H. De novo mutations and rare
variants occurring in NMDA receptors. Curr Opin Physiol 2018;
2: 27–35.
Zhu S, Paoletti P. Allosteric modulators of NMDA receptors: multiple
sites and mechanisms. Curr Opin Pharmacol 2015; 20: 14–23.
92 | BRAIN 2019: 142; 80–92 V. Strehlow et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/1/80/5240919 by R
adboud U
niversity N
ijm
egen user on 18 M
ay 2020
